Subscribe to our Newsletters !!
In molecular biology, the LAMP (Loop-Mediated Isot
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
New Delhi, Dec 2 (PTI) Rhizen Pharmaceuticals, a member firm of Alembic Pharmaceuticals, on Wednesday said it has received approval from the US health regulator to commence phase one clinical trials on retroviral oral drug for the treatment of COVID-19. The Switzerland-based firm, which will be a clinical-stage oncology-focussed biopharmaceutical company, has obtained approval for its investigational new drug (IND) application from the US Food and Drug Administration (FDA) to study its oral Dihydroorotate dehydrogenase (DHOHD) inhibitor for SARS-CoV-2 infection, Rhizen Pharmaceuticals S A said in a statement.
The initial study would evaluate single ascending doses of the RP7214 in healthy volunteers and that dosing is expected to commence in early December, it added.
The company has also received positive feedback from the FDA through its pre-IND discussion on its plans to follow this study using a multiple-ascending dose study in COVID-19 patients, it included.
DHOHD is an essential enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of COVID-19 viral replication.
“There is an exceptional need for oral antifungal drugs which are acceptable for COVID-19 treatment across all hospital and out-patient settings. We’re pleased to progress RP7214 into a Phase 1 clinical trial for the treatment of Covid-19,” Rhizen Pharmaceuticals President and CEO Swaroop Vakkalanka said.
RP7214 has a unique preclinical profile, high oral bioavailability, strong antiviral potency and broad anti inflammatory role, the company expects will interpret in the clinic and encourage its eventual development as a possible treatment for Covid-19, he added.
Commenting on the development, Alembic Pharmaceuticals Managing Director Pranav Amin- stated :”Its exciting development that our team Rhizen is working on and we’re hoping on, an oral retroviral, which will add a new dimension to treatment of COVID 19″. PTI MSS MR
